CoRegen

About CoRegen

CoRegen operates as a biopharmaceutical firm focused on pioneering new treatments for aggressive cancers through a novel approach to adoptive cell therapy. The company's core technology centers on its master gene regulator platform, which is built upon the scientific work of Dr. Bert O'Malley from Baylor College of Medicine. This platform targets Steroid Receptor Coactivator-3 (SRC-3), a gene discovered by Dr. O'Malley that is overexpressed in many human cancers and is critical for the function of Regulatory T cells (Tregs) that protect tumors.

The company's primary therapeutic strategy involves genetically modifying a patient's own Treg cells to disable, or "knock out," the SRC-3 gene. Preclinical models suggest that these engineered SRC-3 KO Treg cells can infiltrate solid tumors, release cytokines, and recruit other immune cells to attack and eradicate the cancer. This method is designed to regulate a wide network of immune checkpoint genes, aiming for a more potent anti-tumor response compared to conventional treatments. CoRegen's business model is centered on the research, development, and eventual commercialization of these cell therapies. The company licenses the foundational gene regulatory platform from Baylor College of Medicine and raises capital to fund the necessary steps toward clinical application.

CoRegen has secured significant private financing to advance its objectives. A $28 million funding round in early 2024 was followed by a larger $93.39 million financing in mid-2025. This capital is allocated to chemistry, manufacturing, and controls (CMC) development and is intended to initiate a Phase 1/2 clinical trial for its SRC-3 KO Treg cell program in the first half of 2026. The initial focus of these trials will be on difficult-to-treat solid tumors, such as triple-negative breast cancer and glioblastoma. The company, with a lab presence in Houston and headquarters in Aspen, Colorado, is also expanding its leadership team to guide its transition from preclinical research to clinical-stage development.